Company / PP&E (Net)
PTC Therapeutics, Inc. PP&E (Net) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$55.4M
FY2025
5-year range
$52.6M / $87.1M
FY2021-FY2025
Trend
-9.2%
vs FY2024
Sector context
#59 of 193
Health Care
What the data says
At $55M, PTC Therapeutics, Inc.'s pp&e (net) ranks #59 of 193 in the Health Care sector. Declined from $87M to $55M over the past 2 years.
Based on SEC 10-K filings.
$55M in FY2025 with a 5-year CAGR of +10.4%.
Declined from $87M to $55M over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -8.6%
- 5-Year CAGR
- +10.4%
- 10-Year CAGR
- -
Sector benchmark
#59 of 193 in Health CareTop 31% of 193This company $55.4M Sector average $777.6M
▼
-92.9% below sector average
Key checks
Key Insights
- 5-year CAGR of +10.4%, indicating consistent growth.
- In FY2025, pp&e (net) decreased 9.2% year-over-year.
- Ranks #59 out of 193 companies in the Health Care sector.
- Peak pp&e (net) was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score 0.95 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $55.4M | -9.2% |
| FY2024 | $61.0M | -30.0% |
| FY2023 | $87.1M | +20.0% |
| FY2022 | $72.6M | +38.0% |
| FY2021 | $52.6M | +55.4% |
| FY2020 | $33.8M | +57.0% |
| FY2019 | $21.5M | +69.8% |
| FY2018 | $12.7M | +51.6% |
| FY2017 | $8.4M | +12.7% |
| FY2016 | $7.4M | -17.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026